Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs
Linda S. Steelman(East Carolina University), James A. McCubrey(East Carolina University), Franca Stivala(University of Catania), Stephen L. Abrams(East Carolina University), Massimo Libra(University of Catania), Jörg Bäsecke(University of Göttingen), Alberto M. Martelli(University of Bologna), Ferdinando Nicoletti(University of Catania), John G. Shelton(Greenville College), Marco Donia(University of Copenhagen), William H. Chappell(University of North Carolina at Chapel Hill)
Cited by 44
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508